The improvement in glycaemic control in T2DM patients achieved by SGLT2 inhibition also led to the consideration to use SGLT2 inhibitors in conjunction with insulin therapy in type 1 diabetes mellitus. Here, SLC5A2 is linked to type 2 diabetes mellitus.